Ethical controversies on the use of placebo as control treatment in clinical trials in neurology;Controversias éticas sobre la utilización de placebo como tratamiento control en los ensayos clínicos en neurología

Neurologia

Volumn 22, Issue 2, 2007, Pages 106-113

  Lahuerta, Juan ^a,e   Gutierrez Rivas E ^b   Frias J ^c   Gracia, D ^d   Dal Re R ^a  

^a Glaxo SmithKline   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e S A   (Spain)

Author keywords

Controlled clinical trial; Ethics; Neurology; Placebo

Indexed keywords

PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; HUMAN; MEDICAL ETHICS; NEUROLOGIC DISEASE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

ALGORITHMS; CLINICAL TRIALS; DRUG THERAPY; ETHICS, RESEARCH; HUMANS; INFORMED CONSENT; NEUROLOGY; PLACEBO EFFECT; PLACEBOS; RISK ASSESSMENT;

EID: 34147139371     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Biller J, Bogousslavsky J. Clinical trials in neurologic practice, vol. 25. Blue books of practical neurology. Boston, Mass: Butterworth Heinemann, 2001.
2. Ashcroft RE, Chadwick DW, Clark SRL, Edwards RHT, Frith L, Hutton JL. Implications of socio-cultural contexts for the ethics of clinical trials. Health Technol Assess 1997;1:1-65.
3. Alves WA, Macciochi SN. Ethical considerations in clinical neuroscience. Current concepts in neuroclinical trials. Stroke 1996;27:1903-9.
4. a ed. New Haven: Yale University Press, 1988.
5. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
6. nd WMA General Assembly. Edinburgh, 2000.
7. Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics 2003;17:188-204.
8. Note of Clarification on paragraph 29 of the WMA Declaration of Helsinki. 2002 (consultado 28/12/2005). Disponible en: www.wma.net/e/policy/b3.htm.
9. Chadwick D, Privitera M. Placebo-controlled trials in neurology: where do they stop? Neurology 1999;52:682-5.
10. a ed. Filadelfia: Lippincott Williams and Wilkins, 2006; p. 469-503.
11. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(Suppl. 1):S57-63.
12. Slack MK, Draugalis JR. Establishing the internal and external validity of experimental studies. Am J Health Syst Pharm 2001;58:2173-81.
13. García-Alonso F, Guallar E, Bakke OM, Carné X. El placebo en ensayos clínicos con medicamentos. Med Clin (Barc) 1997;109:797-801.
14. Cleophas TJ, Zwinderman AH. Limitations of randomized clinical trials. Proposed alternative designs. Clin Chem Lab Med 2000;38:1217-23.
15. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7.
16. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-86.
17. Papakostas YG, Daras MD. Placebos, placebo effect, and the response to healing situation: the evolution of a concept. Epilepsia 2001;42:1614-25.
18. Lublin FD, Reingold SC and the National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. Ann Neurol 2001;49:677-81.
19. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1994;331:1043-9.
20. Pledger GW, Schmidt D. Evaluation of antiepileptic drug efficacy. A review of clinical trial design. Drugs 48;1994:498-509.
21. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999;33:247-62.
22. León AC. Can placebo controls reduce the numbers of nonresponders in clinical trials? A power analytic perspective. Clin Ther 2001;23:596-603.
23. Slyter H. Ethical challenges in stroke research. Stroke 1998;29:1725-9.
24. Kawas CH, Clark CM, Farlow MR, Knopman DS, Marson D, Morris JC, et al. Clinical trials in Alzheimer disease: debate on the use of placebo controls. Alzheimer Dis Assoc Disord 1999;13:124-9.
25. Gutiérrez-Rivas E, Bermejo Pareja F. Aspectos éticos de la investigació n clínica en neurología. En: Pascual J, editor. Ensayo clínico en neurología. Madrid: Ergón, 1998; p. 1-6.
26. Peterson G, Wallin A. Alzheimer disease ethics-Informed consent and related issues in clinical trials: results of a survey among the members of the Research Ethics Committees in Sweden. Int Psychogeriatr 2003;15:157-70.
27. Alzheimer's Association. Research consent for cognitively impaired adults. Recommendations for Institutional Review Boards and investigators. Alzheimer Dis Assoc Disord 2003;18:171-5.
28. Kim SYH, Cox C, Caine ED. Impaired decision-making ability in subjects with Alzheimer's disease and willingness to participate in research. Am J Psychiatry 2002;159:797-802.
29. Real Decreto 223/2004, de 6 de febrero, por el que se regulan los ensayos clínicos con medicamentos. BOE de 7 de febrero de 2004; p. 5429-43.
30. Sachs GA. Advance consent for dementia research. Alzheimer Dis Assoc Disord 1994;8(Suppl. 4):19-27.
31. Ellenberg SS, Temple T. Placebo-controlled and active-controlled trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 2000;133:464-70.
32. Amdur R, Bidle CJ. An algorithm for evaluating the ethics of a placebo-controlled trial. Int J Cancer 2001;96:261-9.
33. Lahuerta J, Gracia D, Casas M, Baca E. ¿Es ético realizar ensayos clínicos controlados con placebo en el desarrollo de un nuevo fármaco para el trastorno depresivo mayor? Relación beneficio/riesgo y consentimiento informado. Conclusiones. Med Clin (Barc) 2004;123:585-90.